Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Insmed Incorporated (Nasdaq: INSM) has announced the granting of inducement awards to 60 new employees, approved by the company's Compensation Committee in accordance with NASDAQ Listing Rule 5635(c)(4).

Rhea-AI Summary

Insmed Incorporated (Nasdaq: INSM) has announced the granting of inducement awards to 60 new employees, approved by the company's Compensation Committee in accordance with NASDAQ Listing Rule 5635(c)(4). On September 3, 2024, the employees received options to purchase a total of 137,140 shares of Insmed common stock at an exercise price of $73.31 per share, which was the closing trading price on the Nasdaq Global Select Market on the grant date.

The options have a 10-year term and a four-year vesting schedule. 25% of the shares will vest on the first anniversary of the grant date, followed by 12.5% vesting every six months thereafter until the fourth anniversary, subject to the employee's continued service with Insmed.

Positive

• Granted stock options to 60 new employees, potentially attracting and retaining talent
• Exercise price of $73.31 per share, aligning with current market value
• 10-year term for options, providing long-term incentive

Negative

• Potential dilution of existing shareholders' equity due to new stock options

Argus Session date unavailable

-2.56% session move Open Argus

Details

News Market Reaction – INSM

The recorded move for INSM in the trading session of this news was -2.56%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BRIDGEWATER, N.J., Sept. 6, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 60 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.

In connection with the commencement of their employment, the employees received options on September 3, 2024 to purchase an aggregate 137,140 shares of Insmed common stock at an exercise price of $73.31 per share, the closing trading price on the Nasdaq Global Select Market on the date of grant.

The options have a 10-year term and a four-year vesting schedule, with 25% of the shares subject to the option vesting on the first anniversary of the relevant grant date and 12.5% of the shares subject to the option vesting every six months thereafter through the fourth anniversary of the relevant grant date, subject to the relevant employee's continued service with Insmed on the applicable vesting date.

About Insmed

Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company's early-stage research programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.

Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Insmed is proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending three consecutive years as the No. 1 Science Top Employer. Visit www.insmed.com to learn more.

Contact:

Investors:

Bryan Dunn
Executive Director, Investor Relations
Insmed
(646) 812-4030
bryan.dunn@insmed.com

Media:

Mandy Fahey
Vice President, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302238489.html

SOURCE Insmed Incorporated

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many new employees received inducement grants from Insmed (INSM) on September 3, 2024?

Insmed (INSM) granted inducement awards to 60 new employees on September 3, 2024.

What is the exercise price of the stock options granted by Insmed (INSM) in the September 2024 inducement awards?

The exercise price of the stock options granted by Insmed (INSM) in the September 2024 inducement awards is $73.31 per share.

What is the vesting schedule for the stock options granted by Insmed (INSM) in September 2024?

The stock options have a four-year vesting schedule, with 25% vesting on the first anniversary and 12.5% vesting every six months thereafter through the fourth anniversary.

How many shares of Insmed (INSM) common stock were included in the September 2024 inducement grants?

The September 2024 inducement grants included options to purchase an aggregate of 137,140 shares of Insmed (INSM) common stock.